BH
Benjamin Hohl sold $353K of ELVN stock
Benjamin Hohl, Chief Financial Officer of Enliven Therapeutics, Inc. (ELVN), sold 6,018 shares of ELVN stock worth $353K, per an SEC Form 4 filed Aug 19, 2026.
The sale was pre-arranged (a 10b5-1 plan or an option exercise), not a fresh decision.
The trade happened on Aug 17, 2026, 2 days before it was made public.
ELVN has moved -20.0% since the trade date, from $59.53 to $47.62 (Nov 16, 2026 close).
- Traded
- Aug 17, 2026
- Disclosed
- Aug 19, 2026
- Filing delay
- 2 days
- Price since
- -20.0%
- Role
- Chief Financial Officer
- Source
- SEC Form 4